Search results for: Precision Medicine

The Evolution of US Policy Responses to the Opioid Epidemic

1 March 2020

The ‘opioid epidemic’ in the US is the most recent drug-abuse challenge from the misuse of prescription medicines or the use of illicit drugs. It is a particularly difficult challenge…

OHE Launches Discussion Paper and Consultation Exercise on Indication-based Pricing

10 May 2019

Increasingly, scientific advances are delivering new medicines that deliver improved survival and quality of life across multiple treatment indications. Indication-Based Pricing (IBP) has been proposed as a way to better…

We Asked, You Answered: Reflections on the First Round of MVAC Feedback

16 May 2019

…some of the main points raised by disease advocacy and access to medicines civil society groups in particular, and how they have influenced our thinking (though of course, we’ll elaborate…

OHE at the 2019 Spanish Health Economics Association (AES) Conference

5 June 2019

…of innovative medicines: the case of risperidone and second-generation antipsychotics This study, co-authored by Mikel Berdud, Bernarda Zamora, and Adrian Towse, aims to guide access decisions and drive the discussion…

Press Release: Proposed International Price Index Effectively Outsources Pharmaceutical Policy Decisions to Other Countries

29 October 2019

…markedly from the U.S. and give the government a central role in purchasing medicines, in contrast to the greater reliance on the private market seen in the U.S.” OHE has…

OHE Awarded Independent Research Organisation (IRO) Status by UKRI

20 May 2020

…UK, there are only 63 IROs in total across all research fields, including areas as diverse as medicine, defence studies, history, and oceanography.  Professor Graham Cookson, OHE’s Chief Executive: We…

Opportunities to Increase Efficiency in Healthcare

6 October 2020

…rational use of medicines, and iv) Healthcare-Associated Infections (HCAIs). Case studies were developed, supplemented by workshops with stakeholders from Poland, Germany, Sweden, The Netherlands, and Spain. We identified examples of…

Virtual ISPOR European 2020

10 November 2020

…presents an in-depth analysis by the OHE on Adaptive Pathways for Tumour Agnostic Medicines in Various Developed Markets. While challenges for Tumour Agnostic medicines are similar in various countries, solutions will likely have…

Value, Affordability, and Decision Making

…evidence generation and comparative assessment for precision medicine. 1 July 2026 Around the world in HTAs: Abu Dhabi – Advancing HTA and value-based healthcare in the UAE Abu Dhabi is…